GlaxoSmithKline Plc’s chief executive officer Andrew Witty? said the UK’s largest drugmaker may buy assets in India in the price range of $1-2 billion to expand sales in the world’s second-fastest growing major economy. “We are not in a hurry to grab such an opportunity at the current high premium valuation,” Witty said on Tuesday. “We are already big in this market and not desperate to grow through a high premium deal.” The Glaxo global head did not specify the timeline for such a purchase or the type of company it is interested in. Witty had said Glaxo will look forward to growth opportunities including acquisitions in the country when he visited India after taking over as chief executive of the company.
